Project: The first broad-spectrum cure against pandemic-prone flaviviral infections: West Nile, Zika & Dengue

Acronym	FLAVICURE (Reference Number: 113923)
Duration	01/05/2020 - 01/01/2024
Project Topic	FLAVICURE will deliver a broad-spectrum antiviral for treatment of infections caused by flaviviruses West Nile, Zika and dengue. Partners will use their proprietary drug discovery engine to develop novel flavivirus protease inhibitors. The project covers preclinical development required to generate the data package for subsequent regulatory validation to progress the candidate to clinical studies. The drug will prevent spread of outbreaks, cure early-stage infection and halt disease progression.
Network	Eurostars 2
Call	Eurostars Cut–off 12

Project partner

Number	Name	Role	Country
1	Chimera Biotec GmbH	Partner	Germany
2	Fraunhofer IZI	Partner	Germany
3	Protinhi Therapeutics	Coordinator	Netherlands